- Record: found
- Abstract: found
- Article: not found
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
Jaap Verweij
1 ,
Paolo G Casali ,
John Zalcberg ,
Axel LeCesne ,
Peter Reichardt ,
Jean-Yves Blay ,
Rolf Issels ,
Allan van Oosterom ,
Pancras C W Hogendoorn ,
Martine Van Glabbeke ,
Rossella Bertulli ,
Ian Judson
September 29 2004
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST). We aimed to assess dose dependency of response and progression-free survival with imatinib for metastatic GIST.